Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12118691 | 0.85 | DGAT1 (0.44) | DGAT1BRD4CREBBP | |
| SCHEMBL12118635 | 0.85 | DGAT1 (0.44) | DGAT1BRD4CREBBP | |
| SCHEMBL22126034 | 0.82 | DGAT1 (0.38) | DGAT1BRD4CREBBP | |
| SCHEMBL22126015 | 0.82 | DGAT1 (0.38) | DGAT1BRD4CREBBP | |
| SCHEMBL22126045 | 0.81 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL22126056 | 0.81 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL23163189 | 0.80 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL31710909 | 0.80 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL3640273 | 0.80 | DGAT1 (0.39) | DGAT1BRD4CREBBP | |
| SCHEMBL31710735 | 0.80 | DGAT1 (0.49) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4537902-A2 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3773577-B1 | TRICYCLIC ASK1 INHIBITORS | TERNS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| EP-3773577-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10919911-B2 | Tricyclic ASK1 inhibitors | Terns, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2019200267-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019200267-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190315767-A1 | TRICYCLIC ASK1 INHIBITORS | Terns, Inc. (US) | 2019-10-17 | — | — | US | disclosed |
| US-8735388-B2 | Heterocyclic compounds with affinity to muscarinic receptors | ABBVIE B.V. (NL) | 2014-05-27 | — | — | US | disclosed |
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. | 2012-04-19 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| EP-2150543-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | Solvay Pharmaceuticals B.V. (NL) | 2010-02-10 | — | — | EP | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| WO-2008129054-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129054-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095039-A1 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | DGAT1 3057/4885BRD4 694/4885CREBBP 1793/4885 |
| US-10919911-B2 | Tricyclic ASK1 inhibitors | MAP3K1, MAP3K8, MAP3K20 | DGAT1 1372/4885BRD4 1094/4885CREBBP 408/4885 |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | CHRM3, CHRM2, CHRM1 | DGAT1 2362/4885BRD4 842/4885CREBBP 2445/4885 |
| US-20190315767-A1 | TRICYCLIC ASK1 INHIBITORS | MAP3K1, MAP3K8, MAP3K20 | DGAT1 1372/4885BRD4 1094/4885CREBBP 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.